ALK increases sales in Q2, but operating result decreases
Wednesday morning, allergy company ALK presented the full report for the year's second quarter. The central figures were known ahead of time, since the company upgraded its guidance on Monday.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Wednesday morning, pharmaceutical company ALK shed light on the last unknown figures in the company's Q2 report. Since the firm published the main figures for the quarter on Monday, there were no great surprises.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.